Reviewed by the PeptideMind Team · Updated August 5, 2026

ARA-290 Peptide (Cibinetide) Dosage Guide, Benefits & Side Effects

ARA-290 peptide (Cibinetide) dosage guide for nerve pain and neuropathy: how it regenerates small nerve fibers and reduces inflammation, plus Phase 2 trial data and dosing protocols.

Basic Dosage Calculator

Calculate peptide doses with our visual syringe guide.

Peptide per vial

Target research quantity

Bac water added

As seen on

Ara 290 Dosage Schedule

A daily dose studied for supporting nerve repair and easing nerve-related pain, for people dealing with ongoing discomfort rather than an acute injury.

Ara 290 Nerve Repair Protocol

8 weeks, focused on healing and recovery.

Daily dosing

Taken daily.

4 mg per injection

4 mg per injection, given just under the skin in the abdomen or thigh.

Ara 290 may help repair nerves and reduce pain.

September 2026

Sun

Mon

Tue

Wed

Thu

Fri

Sat

What is Ara 290?

ARA 290 (also called Cibinetide) is a small, lab-made peptide based on part of the hormone erythropoietin (EPO), but modified so it doesn't affect red blood cells the way EPO does. Instead, it targets a repair pathway in the body that can help heal damaged nerves and calm inflammation. It's being studied mainly for nerve pain conditions and inflammatory disorders, and has shown promising results in human studies.

Healing

Research targets include tissue repair, wound healing, and recovery from injury.

Cognitive

Research targets include neural signaling, memory formation, and mental clarity pathways.

Healing

ara

Cognitive

Our top-rated vendor

Our rankings are based solely on third-party lab testing rigor, COA transparency, and pricing, no paid placements, no affiliate influence. We update this list as new data comes in.

Based on current scores, this vendor ranks highest across those criteria.

Protide Health

#1 Rated Research Peptide Supplier

Visit site

View all vendors

What Does Ara 290 Do?

It locks onto a repair-signaling receptor found on damaged tissue, calming inflammatory alarm systems inside cells and dialing down inflammation-triggering proteins. That same signal also encourages damaged small nerve fibers to regrow.

Binds a repair receptor

Locks onto a signaling receptor found on damaged tissue.

Calms inflammation

Dials down inflammatory alarm systems inside cells.

Helps nerves regrow

Encourages damaged small nerve fibers to regenerate.

Frequently Asked Questions About Ara 290

Straight answers on reconstitution, dosing, and safety, everything you need to research with confidence. For research reference only.

Ara 290 (also called cibinetide) is a synthetic 11-amino-acid peptide derived from the structure of erythropoietin (EPO). It was engineered to selectively activate the 'innate repair receptor' (a complex of the EPO receptor and CD131/beta-common receptor) without binding the classical EPO receptor that stimulates red blood cell production. This means it is designed to trigger EPO's tissue-protective, anti-inflammatory, and nerve-repair signaling without the erythropoietic (blood-thickening) side effects associated with EPO itself.

Ara 290 was developed by Araim Pharmaceuticals and tested in several Phase 2 clinical trials, primarily in people with sarcoidosis-associated small fiber neuropathy and type 2 diabetic neuropathy. Studies used doses in the 2-4 mg range (subcutaneous or IV) daily or several times weekly for about 28 days, and reported improvements in neuropathic symptom scores, corneal nerve fiber density, and some metabolic markers (e.g., HbA1c, lipids) versus placebo. No Phase 3 trials have been completed, and as of 2026 the original sponsor has ceased operations, so clinical development has largely stalled.

Across published trials, doses ranged from about 1-8 mg per day, with 4 mg daily identified as a target dose showing benefit without additional gains at higher doses. Typical protocols used daily subcutaneous injections for approximately 4 weeks, though some studies used intravenous dosing several times per week. These figures come from controlled clinical research settings, not from an approved dosing label, since Ara 290 has no approved human dosage.

In published trials, Ara 290 was generally well tolerated, with mild side effects and no dose-limiting toxicity reported at studied doses. Because it does not appreciably raise red blood cell counts the way EPO does, it appears to avoid EPO's clotting/blood-viscosity risks. That said, safety data comes only from small, short-duration Phase 2 studies; long-term safety, rare adverse effects, and interactions have not been established in humans.

Like most research peptides, lyophilized (freeze-dried) Ara 290 is generally kept refrigerated or frozen before reconstitution and protected from light. After being mixed with bacteriostatic or sterile water, it is commonly stored refrigerated (about 2-8°C) and used within a limited window, as peptides degrade faster once in liquid form. Specific stability data for commercial (non-pharmaceutical-grade) vials has not been independently verified.

No. Although Ara 290 is derived from the EPO molecule, it was specifically modified to avoid activating the classical EPO receptor responsible for stimulating red blood cell production. Research suggests it does not meaningfully increase hematocrit or red blood cell counts, which is different from EPO's primary athletic-doping mechanism. It is being investigated for tissue-protective and anti-inflammatory effects rather than performance enhancement.

Ara 290 Reconstitution Guide

Ara 290 is supplied as a freeze-dried powder that must be mixed into a injectable solution before use. Available in 10mg, 15mg, 16mg sizes.

5 mg lyophilized vial

Ara 290 is supplied as a freeze-dried powder that must be mixed into a injectable solution before use. Available in 10mg, 15mg, 16mg sizes.

2 mL bacteriostatic water

Adding 2 mL of bac water to a 5 mg vial gives a workable concentration for syringe dosing. More water makes microdosing easier; less concentrates each draw.

Storage after mixing

The dry powder lasts up to two years in the fridge or three years in the freezer, kept away from light. Once mixed with liquid, refrigerate and use within about a month, and never freeze it again. After reconstitution, keep the vial refrigerated and use within 30 days.

Reconstitution steps

Remove caps & sanitize stoppers

Attach needle to syringe

Draw 2 mL bacteriostatic water

Insert needle into Ara 290 vial

Release water gently down the side

Swirl to dissolve — don't shake

Check for full dissolution

Refrigerate Ara 290 — good for 30 days

Chemical Makeup

Amino Acids

Ara 290

Position 1

Glu

Position 2

Gln

Position 3

Leu

Position 4

Glu

Position 5

Arg

Position 6

Ala

Position 7

Leu

Position 8

Asn

Position 9

Ser

Position 10

Ser

Position 11

Amino acid sequence

?Position 1

Glutamic acidPosition 2

GlutaminePosition 3

LeucinePosition 4

Glutamic acidPosition 5

ArgininePosition 6

AlaninePosition 7

LeucinePosition 8

AsparaginePosition 9

SerinePosition 10

SerinePosition 11

What Are the Benefits of Ara 290?

What research says it may help with, and how it works in the body.

neuroprotection

: Increased the area of nerve fibers in the cornea (eye surface) by 23%, along with lasting improvement in pain.
: Able to pass into the brain (crossing the blood-brain barrier) to help protect brain cells after stroke or traumatic brain injury.
: Helped nerves regenerate and improved metabolic measures in people with Type 2 diabetes.

tissue repair

: Speeds up skin healing (regrowth of the outer skin layer) and new blood vessel formation by increasing a growth factor called VEGF.
: Helped preserve heart function in aging studies.
: In heart attack studies, it reduced the amount of heart tissue damaged.

antiinflammatory

: Reduced the severity of colon inflammation (colitis) in animal studies.
: Helps transplanted tissue survive longer and lowers the chance of the body rejecting it.
: Lowers production of several inflammation-triggering substances in the body (TNF-alpha, IL-6, and IL-12).

What Are the Side Effects of Ara 290?

Who should avoid it, warning signs to watch for, and what to know before combining it with other compounds.

Who Should Avoid It

: Recent anti-TNF therapy (within 6 months)
: EPO use (within 2 months)
: Pregnancy
: BMI > 34 kg/m²

Stop Right Away If You Notice

: Severe injection site reactions
: Unexpected blood count changes
: Allergic reaction signs
: Worsening of underlying condition
: New neurological symptoms
: Any serious adverse events

Milder Signs to Watch For

Cloudy or discolored solution indicates degradation; should be clear to slightly cloudy

Was it helpful?Yes

Is Ara 290 FDA approved?

Ara 290 is not an FDA-approved drug. It is intended for research purposes only and is not approved for human consumption, diagnostic, or therapeutic use.

Research Use Only

Ara 290 has not been evaluated by the FDA for safety or efficacy in humans.

No Clinical Oversight

Not manufactured under FDA-regulated quality or clinical standards.

Unregulated Sourcing

Purity, dosing, and sourcing are not verified through FDA testing or oversight.

A smartphone screen displaying FDA status for a drug, indicating "FDA approved drug: No" and "Classification: Research use only." A banner notes "Research Only" with the disclaimer "not for human use," emphasizing its intended use for laboratory and analytical purposes.

Ara 290 Cycle Length: How Long Should It Last?

This breaks down how long a typical Ara 290 cycle runs and what research suggests happens at each stage. Research shows that staying on a peptide continuously, without a break, may make it less effective over time.

That's why most research protocols build in a break between cycles, often called a washout period, to let the body reset before starting again.

Week 1-2: Initial anti-inflammatory effects and mild pain symptom improvement
Week 2-4: Progressive nerve regeneration, improved tissue healing markers
Week 4-6: Peak therapeutic effects, maximum nerve fiber density improvements
Month 2-6: Long-lasting benefits via molecular switch effect

Ara 290 Research References

It is a phase 2 compound

5Research references

Ara 290

Ara 290 is a phase 2 compound

Sarcoidosis Neuropathy Phase 2b Trial

64 patients, 1-8 mg SC daily for 28 days: 23% increase in corneal nerve fiber area at 4 mg dose.

2017

Diabetic Macular Edema Pilot Study

9 patients, 4 mg SC daily for 12 weeks: Improved quality of life; good safety profile.

2020

Myocardial Infarction Protection Study

Preclinical mouse model, 24 μg/kg IV single dose: Reduced infarct size and improved survival.

2012

Stroke Neuroprotection Research

Rat stroke model, 300 μg/kg IV single dose: Reduced stroke volume; BBB penetration confirmed.

2011

Type 2 Diabetes Neuropathy Phase 2

48 patients, 4 mg SC daily for 28 days: Sustained HbA1c improvement and nerve regeneration.

2015

Browse user-created protocols

Real protocols from the community that include Ara 290

View all protocols

Recovery & Clarity Stack

167days

7 peptides·Healing·26d ago

Jacinta

Healing

klw

Healing

ara

Weight

aod

ARA-290 Peptide (Cibinetide) Dosage Guide, Benefits & Side Effects

Ara 290 Dosage Schedule